Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > We will never know

<< Previous

Bullboard Posts

Next >>

Post by Layth1990on Jan 27, 2021 5:21pm

237 Views

Post# 32402588

We will never know

We might wake up tomorrow with partnership news, or listing. No one really knows what will happen tomorrow since those kind of news/information are kept confidential until the release.

people who sold today might regret that tomorrow, that is why it is important to hold long.If it goes down , no problem i will add more. Cheers

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale